<DOC>
	<DOC>NCT00625443</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of AKR-501 administered in patients with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study treatment in Protocol 501-CL-003.</brief_summary>
	<brief_title>Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003</brief_title>
	<detailed_description>Patients eligible to enroll into this rollover protocol will begin study treatment within 2-5 days of their Day 28 study termination visit in Protocol 501-CL-003. Patients who met the primary efficacy response criterion in Protocol 501-CL-003 will continue receiving the same study treatment to which they were assigned in the previous protocol in a double-blinded manner, these being one of the following 5 treatments: - AKR-501 2.5 mg daily - AKR-501 5 mg daily - AKR-501 10 mg daily - AKR-501 20 mg daily - Placebo Patients who did not meet the primary efficacy response criterion in Protocol 501-CL-003 who otherwise meet the eligibility criteria for this rollover protocol will be offered open label AKR-501 10 mg daily. This is a parallel group, rollover study.</detailed_description>
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>1. Patients who completed 28 days of study treatment in Protocol 501CL003. 2. No significant safety or tolerability concerns from the patient's participation of Protocol 501CL003 as determined by the Investigator. 3. Received medical monitor approval for enrollment into this study. 4. Patients receiving maintenance corticosteroids may be enrolled, as long as the corticosteroids have been administered at a stable dose and the Investigator does not foresee the need to change the steroid dose during study participation. Patients should remain on this stable corticosteroid dose during study participation. 5. Women of childbearing potential must have a negative serum pregnancy test at the Day 28 assessment in Protocol 501CL003. (Childbearing potential is defined as any woman who has not been surgically sterilized and is premenopausal or perimenopausal i.e., any menstrual flow within 12 months of Screening Visit A for Protocol 501CL003). 6. Women of childbearing potential must agree to practice a medically approved form of contraception (one of the following must be used: condoms (male or female) with a spermicidal agent, diaphragm or cervical cap with a spermicidal agent, IUD,hormonal contraception, abstinence). 7. Willing and able to provide written informed consent. 1. Women who are pregnant and/or lactating. 2. Use of the following drugs or treatments: Rituximab Azathioprine, Cyclosporine A, or other immunosuppressant therapy Aspirin, Aspirincontaining compounds, Salicylates,Anticoagulants, Nonsteroidal antiinflammatory drugs(NSAIDs)(including Cyclooxygenase2 [COX2] specific NSAIDs), clopidogrel; ticlopidine; and any drugs that affect platelet function. Danazol Rh0(D) immune globulin (WinRhoÂ®) or intravenous immunoglobulin (IVIG). 3. Inability to comply with protocol requirements or give informed consent, as determined by the Investigator. For more information regarding inclusion/exclusion criteria, please see record for AKR 501CL003 Protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>ITP</keyword>
	<keyword>Chronic Idiopathic Thrombocytopenic Purpura</keyword>
</DOC>